Industry Satellite Symposia

The 2026 Multidisciplinary Head and Neck Cancers Symposium Education Team has reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposia (ISS). The ISS constitutes the content and views of the sponsor and is not part of the official 2026 Multidisciplinary Head and Neck Cancers Symposium program.


Thursday, February 19

Sinatra Ballroom 9-11
12:00 p.m. - 12:30 p.m.: Registration and Lunch
12:30 p.m. - 1:30 p.m.: In-Person and Virtual Symposium

New Immunotherapy Frontiers in R/M HNSCC: Multidisciplinary Perspectives on Advancing Care in Challenging Patient Populations

Register or learn more.

Learning Objectives 

Upon completion of this activity, learners will:

  • Cite updated evidence and practice guidelines supporting emerging immune-based therapeutics for the management of head and neck squamous cell carcinoma (HNSCC)
  • Develop multidisciplinary care plans that integrate novel immunotherapy options into the personalized treatment of advanced HNSCC
  • Utilize team-based strategies to address the practical aspects of immune-based treatment for HNSCC, including care planning, delivery of therapy, and management of adverse events

Target Audience: This activity has been designed to meet the educational needs of oncologists, radiologists, surgeons, nurses, and other health care professionals involved in the care of patients with head and neck cancer.

Program Agenda

  • Introduction: Current Realities and Future Opportunities with Immunotherapy in HNSCC
  • Seminar and Tumor Board: Preparing for Immunotherapy with Bispecifics and Other Emerging Strategies
  • Concluding Remarks and Audience Q&A

Faculty

  • Barbara Burtness, MD (Chair)
    Anthony N. Brady Professor of Medicine
    Chief Translational Research Officer
    Associate Director, Translational Research
    Co-Leader, Developmental Therapeutics Program
    Chief, Head and Neck/Sarcoma Oncology
    Yale Cancer Center/Yale School of Medicine
    New Haven, Connecticut
  • Aarti Bhatia, MD, MPH
    Associate Professor, Internal Medicine (Medical Oncology)
    Yale Cancer Center
    New Haven, Connecticut
  • Ranee Mehra, MD
    Professor of Medicine
    Associate Director for Clinical Research
    Solid Tumor Section Head
    Director, Head and Neck Medical Oncology
    University of Maryland Greenebaum Comprehensive Cancer Center
    Baltimore

Accreditation Statement
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation Statements
For Physicians
PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Associates
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the health care team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

This activity is supported by independent educational grants from Johnson & Johnson and Merus.


Sinatra Ballroom 9-11
5:30 p.m. - 7:00 p.m.: Symposium

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

Learning Objectives 

Upon completion of this activity, learners will:

  • Incorporate guideline recommendations for post-CRT surveillance to ensure timely intervention for patients with LA-HNSCC
  • Apply risk-stratified strategies to determine appropriate post-CRT management for patients with LA-NSCC
  • Implement coordinated multidisciplinary care plans to mitigate and manage toxicities related to CRT in patients with HNSCC
  • Identify potentially eligible patients for ongoing clinical trials evaluating novel post-CRT treatment approaches

Target Audience: This educational activity is directed toward medical oncologists, radiation oncologists, head and neck surgery/ENT, speech-language pathologists, NPs/PAs, nurses, pharmacists, and other HCPs involved in the treatment and management of LA-HNSCC.

Program Agenda

  • Welcome and Introductions
  • Setting the Stage: Current Standards for Post-CRT Care in LA-HNSCC
  • Case 1: HPV-Positive LA-HNSCC After CRT
  • Case 2: HPV-Negative / Smoking-Associated LA-HNSCC After CRT
  • Optimizing Multidisciplinary Care: Surveillance and Toxicity Management Pathways
  • Investigational Horizon: Emerging Consolidation Strategies
  • Post session Assessment, Questions and Answers, and Conclusions

Accreditation Statement
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hour.

This activity is supported by an independent educational grant from AstraZeneca.


Sinatra Ballroom 12-14
5:00 p.m. - 5:30 p.m.: Registration and Dinner
5:30 p.m. - 7:00 p.m.: Symposium

Multidisciplinary Momentum in Head and Neck Cancers: Elevating Care Across SCCHN and NPC

Register or learn more.

Learning Objectives 
Upon completion of this activity, learners will:

  • Describe the key advances in systemic therapy for H&N cancers
  • Apply evidence-based diagnostic and staging strategies for the accurate classification of H&N cancer
  • Customize treatment approaches for patients with H&N cancer
  • Proactively identify and manage treatment-related toxicities to preserve function and improve quality of life
  • Explain the importance of multidisciplinary care in H&N cancer and how best to apply it for optimal outcomes
Target Audience: The target audience is oncologists (including radiation oncologists), pathologists (including head and neck surgeons), radiologists, nurse practitioners (NPs), physician assistants (PAs), and other members of the multidisciplinary oncology care team.

Accreditation Statement
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation Statement
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an independent educational grant from Coherus Oncology.


Friday, February 20

Sinatra Ballroom 9-11

5:00 p.m. - 5:30 p.m.: Hors d'oeuvres and Registration
5:30 p.m. - 6:30 p.m.: In-Person and Virtual Symposium

Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV Associated Recurrent/Metastatic Head and Neck Cancer

Register or learn more.

Learning Objectives

Upon completion of this activity, learners will:

  • Explain the implications of human papillomavirus (HPV) status in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) for patient outcomes and quality of life
  • Interpret clinical trial data stratified by HPV status to identify limitations of current standard-of-care therapies for non-HPV-associated recurrent/metastatic HNSCC
  • Explain how tumor microenvironment factors influence treatment resistance and differential outcomes in non-HPV-associated vs HPV-positive oropharyngeal cancer (OPC)
  • Evaluate investigational therapies for non-HPV-associated recurrent/metastatic HNSCC and assess their potential to address unmet clinical needs

Target Audience: Medical oncologists, radiation oncologists, oncology surgeons, and other health care professionals involved in the care of patients with head and neck cancer.

Program Agenda

  • Welcome and Introductions
  • Two Diseases, One Name: Why Non-HPV Associated R/M Head and Neck Cancer Demands Its Own Strategy
  • The Data Divide: Uncovering the Divergence in Treatment Outcomes Based on Primary Tumor Site and HPV Status
  • How Tumors Build Barriers: Implications of the Microenvironment in Treatment Resistance of Non-HPV Associated R/M Head and Neck Cancer
  • From MOA to Medicine: Translating Knowledge of Therapeutic Innovation in Non-HPV Associated R/M Head and Neck Cancer
  • "Ask the Faculty" and Take-Home Messages

Faculty

  • Trisha Wise-Draper, MD, PhD (Chair)
    University of Cincinnati
    UC Health
    Cincinnati
  • Christine Chung, MD
    Moffitt Cancer Center
    University of South Florida
    Tampa, Florida
  • Renata Ferrarotto, MD
    University of Texas MD Anderson Cancer Center
    Houston
  • Kevin Harrington, PhD, FRCP, FRCR
    The Institute of Cancer Research
    The Royal Marsden NHS Foundation Trust
    London, United Kingdom

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Europe and PeerVoice. Siyemi Europe is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
Siyemi Europe designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credits™ into European CME credit (ECMEC) should contact the UEMS.

This activity is supported by an independent educational grant from Bicara Therapeutics.

CO-SPONSORED BY:

TERMS OF USE & PRIVACY POLICY

 

Connect With Us: